64th American College of Rheumatology and 35th Association of Rheumatology Health Professionals Annual Scientific Meetings October 29 - November 2, 2000 Philadelphia, Pennsylvania The independent, confirmatory evidence of the long term disease-modifying effect by Glucosamine Sulfate (DONA™) Glucosamine Sulfate decreases progression of knee osteoarthritis in a long-term,randomised, placebo-controlled,independent,confirmatory trial. Karel Pavelka,et al. Follow-up studies to the former evidence of the disease-modifying effect by Glucosamine Sulfate (DONA™) Biochemical markers and Disease Modification Cartilage degradation in knee osteoarthrithis patients with elevated levels of urinary collagen type II C-Telopeptide fragments. Stephan Christgau,et al. Changes in serum osteocalcin but not other serum and urinary markers of bone and cartilage metabolism,measured after 12 months,are significantly correlated to long-term (36 months) structural changes in knee osteoarthritis (OA).. Jean-Yves Reginster,et al. Biochemical markers of bone and cartilage remodeling are poorly correlated with clinical and radiological severity of knee osteoarthritis. Jean-Yves Reginster,et al. Efficacy of Glucosamine Sulfate (DONA™) on symptoms of OA at different joint localizations. Efficacy of Glucosamine Sulfate in osteoarthritis of the lumbar spine:a placebo-controlled, randomized,double-blind study. Klaus K Foerster,et al.   THE LANCET PUBLISHES STUDY CONFIRMING DONA™ REDUCES PROGRESSION OF OSTEOARTHRITIS January 27, 2001 London, UK

Copyrights © 2000 Rotta Pharmaceuticals, Inc. Wall, NJ, USA. All rights reserved.